Skip to main content
. 2013 Aug 19;8(8):e71865. doi: 10.1371/journal.pone.0071865

Figure 2. Efficacy of SELENBP1 in discriminating NBE from preneoplastic lesions(SM, AH and CIS) from invasive LSCC.

Figure 2

Receiver operating characteristic (ROC) curves of SELENBP1 in discriminating NBE from preneoplastic lesions, NBE from invasive LSCC, and preneoplastic lesions from invasive LSCC.